Provider review
Hims & Hers Review (2026)
The category's biggest consumer brand, now with FDA-approved Wegovy
TL;DR
- Starting price
- $199/mo
- Maintenance
- $249/mo
- 12-month true total
- $2,938
- Editorial verdict
- 4.2 / 5
The largest direct-to-consumer telehealth brand in the category. Launched a Novo Nordisk Wegovy partnership in March 2026, giving members a route to the FDA-approved brand alongside their existing compounded semaglutide program.
Quick facts
| Criterion | Hims & Hers |
|---|---|
| Starting price (month 1) | $199/mo |
| Maintenance monthly price | $249/mo |
| 12-month true total | $2,938 |
| Medications offered | Compounded Semaglutide (injection), Brand-name Wegovy (via Novo Nordisk partnership), Oral GLP-1 blend |
| FDA-approved options available | Yes |
| Compounded options available | Yes |
| Consultation format | Asynchronous |
| States served | All 50 states |
| Coaching included | Available as add-on |
| Cancellation policy | Monthly, no long-term contract; cancel any time via the app |
| Prescription turnaround (SLA) | See provider review |
| Lab work required | See provider review |
| Customer support hours | See provider review |
| Trustpilot score | 4.3 / 5 (28,500 reviews) |
| FDA warning letter history | Received 2025-09-12 · resolved |
Who this is for
- Readers who want brand recognition and a polished app experience
- Readers looking for FDA-approved Wegovy via the Novo Nordisk partnership
- Members who value mobile-first refills and quick re-consults
Who should look elsewhere
- Readers hunting for the lowest 12-month total in the category
- Readers who want synchronous (live) clinical consultations
Pricing deep-dive
Hims & Hers lists a starting price of $199/month. From month two onward, the sustained price is $249/month. Our honest 12-month rollup — month-1 intro plus eleven months at the maintenance rate — comes to $2,938.
Starting price reflects month-1 compounded semaglutide promotional rate. Maintenance reflects the sustained monthly price at typical maintenance dose. 12-month total is our rollup of intro + maintenance, not the provider's advertised figure. Wegovy pricing via the Novo Nordisk partnership is tracked separately in the medications table.
Medications offered
| Medication | Form | FDA status | Monthly |
|---|---|---|---|
| Compounded Semaglutide (injection) | injection | compounded | $199/mo |
| Brand-name Wegovy (via Novo Nordisk partnership) | injection | FDA-approved | $499/mo |
| Oral GLP-1 blend | oral | compounded | $79/mo |
Compounded medications are prepared by 503A or 503B pharmacies under the FDA’s compounding framework. They are not the same as FDA-approved brand-name Wegovy or Zepbound. Read our explainer.
Regulatory & risk snapshot
Class action status: None active on record.
States served: All 50 states
Common side effects
GLP-1 medications carry a recognized side-effect profile. Reported effects include:
- Gastrointestinal (GI) symptoms — nausea, vomiting, diarrhea, constipation; most common during titration.
- Pancreatitis risk — discontinue and seek care if you develop persistent severe abdominal pain.
- Thyroid concerns — these medications carry a boxed warning for thyroid C-cell tumors observed in rodents.
- Other reported effects — gallbladder disease, kidney injury (often dehydration-mediated), injection-site reactions, and hypoglycemia (especially with insulin or sulfonylurea use).
This list is not exhaustive. Individual results vary; clinical-trial outcomes may not reflect typical user experience. Discuss your full medical history with a qualified healthcare professional before starting treatment.
Who should not take GLP-1 medications
GLP-1 medications are not appropriate for everyone. You should not start treatment if any of the following apply:
- Personal or family history of medullary thyroid cancer (MTC).
- Personal or family history of multiple endocrine neoplasia type 2 (MEN 2).
- Current pregnancy, planned pregnancy, or breastfeeding — discontinue at least two months before a planned pregnancy.
- Known hypersensitivity to semaglutide, tirzepatide, or any inactive ingredient in the product.
- Prior history of pancreatitis (relative contraindication — discuss with your prescribing clinician).
This list summarizes the labeled contraindications and is not a substitute for medical evaluation. A qualified healthcare professional must review your history before any prescription is issued.
What real users say
Aggregated from public sources. We do not publish individual testimonials.
Reddit sentiment: Broadly positive on app experience, shipping reliability, and re-consult speed. Recurring complaints focus on the intro-to-maintenance price jump and the difficulty of reaching a live clinician for dose questions. Cassie to pull current thread digest on next weekly crawl.
Our verdict
The largest direct-to-consumer telehealth brand in the category. Launched a Novo Nordisk Wegovy partnership in March 2026, giving members a route to the FDA-approved brand alongside their existing compounded semaglutide program. We score Hims & Hers at 4.2 / 5 overall.
- price
- 3 / 5
- clinical
- 4 / 5
- transparency
- 4 / 5
- support
- 4 / 5
Alternatives worth considering
Henry Meds
Flat $179/month — traded its aggressive-intro model for predictable mid-tier pricing
Ro
Hybrid clinical model with dedicated coaching and human follow-up
Zealthy
The insurance-navigation play — helps members route to covered Wegovy/Zepbound
Frequently asked questions
- How much does Hims & Hers actually cost over 12 months?
- Our 12-month true cost calculation for Hims & Hers is $2,938, rolling up the month-1 price of $199 and the sustained maintenance price of $249/month.
- Is Hims & Hers safe?
- Hims & Hers operates as a fully asynchronous telehealth provider. Like any GLP-1 program, individual safety depends on your medical history — consult a qualified healthcare professional before starting any weight-loss treatment, and review our Regulatory & Risk section below for known issues.
- Does Hims & Hers accept insurance?
- Insurance acceptance varies by plan and medication. Programs that offer brand-name FDA-approved options (Wegovy, Zepbound) can often route prior authorization; compounded-only programs generally do not bill insurance.